Upjohn's Theodore Cooper
Executive Summary
Company Chairman and CEO, age 64, died April 22 of complications of cancer. Prior to joining Upjohn as a board member in 1978, Cooper served as HHS assistant secretary for health and associate director of the National Heart, Lung and Blood Institute and as dean of Cornell University Medical School. Cooper was named exec VP at Upjohn in 1980, vice chairman in 1984 and chairman and CEO in 1987. A search committee for his successor will be headed by Upjohn board member, and former Kellogg chairman, William LaMothe. Upjohn President Ley Smith will continue as acting chairman and CEO ("The Pink Sheet" April 19, T&G-2).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth